SGLT2 inhibitors: A game-changer in preventing heart failure and sudden cardiac deaths

FHS
April 9, 2024
4:45 am

study reveals that SGLT2 inhibitors consistently lower the risk of major adverse cardiovascular events by 9% across various patient groups, especially impacting cardiovascular death reduction, highlighting their broad therapeutic potential beyond diabetes management.

Ulotaront hydrochloride by Sumitomo Pharma America for Schizophrenia: Likelihood of Approval

Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Schizophrenia.

March 19, 2024

$3.3 million study to explore eye health in patients with prediabetes and diabetes

A $3.3 million study at the University of Houston College of Optometry will track the health of patients with prediabetes and diabetes to find out

August 19, 2024

eGenesis scoops $191m for genetically modified pig kidney transplant trial – Pharmaceutical Technology

eGenesis says its modified organs can alleviate transplant waitlists while PETA condemns the approach. Image credit: Shutterstock / Lightspring. Investors are rallying around the promise

September 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.